To analyze the impact of neoadjuvant chemotherapy (CT) on the treatment of early-stage nasopharyngeal carcinoma (NPC) as compared with radiotherapy (RT) alone.
INTRODUCTION
Although concurrent chemoradiotherapy (CCRT) with or without adjuvant chemotherapy (CT) has been proven superior to radiotherapy (RT) alone in the treatment of advanced nasopharyngeal carcinoma (NPC) as determined in several prospective randomized trials [1] [2] [3] [4] [5] and meta-analyses, 6 -8 RT alone has been the standard treatment for earlystage NPC. Because many previous randomized trials for NPC have used different stage systems including the 1992 American Joint Committee on Cancer (AJCC) system and Ho's stage, a standard treatment for 1997 AJCC stage 9 I to II is not well defined. It has been traditionally thought that RT alone is sufficient treatment for stage I to II NPC. However, Chua et al. 10 have observed that patients with stage I disease have an excellent outcome with RT alone, and patients with stage II disease, especially those with T1 to T2N1 disease, have a relatively worse outcome. Although CCRT is being recommended to the patients with stage IIB disease in the National Comprehensive Cancer Network guideline, its persuasive power is weak. 11 There are few studies comparing RT alone with combined therapy in early-stage NPC. Chua et al. 12 have observed that neoadjuvant CT improves overall survival (OS) and reduces the risk of distant metastases significantly for patients with stage IIB disease on meta-analysis of two prospective, randomized studies. 13, 14 Cheng et al. 15 have reported that stage II disease with CCRT showed an equal disease-free survival (DFS) compared with stage I disease with RT alone.
Recognizing that we have treated many early-stage NPC patients with induction CT for past 20 years and that we have observed the benefit of neoadjuvant CT in advanced NPC patients, 16 we now want to know whether neoadjuvant CT is beneficial for early-stage NPC patients. This retrospective study analyzed the outcomes of patients with early-stage NPC who were treated with either RT alone or with neoadjuvant CT followed by RT (CT/RT).
MATERIALS AND METHODS
Between October 1986 and May 2004, 291 patients with histologically proven NPC were given definitive RT with or without CT at the Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea. Medical records of these patients that included baseline endoscopic findings, computed tomography scans, and magnetic resonance images (MRI) were retrieved and reviewed. Using this information, we were able to restage all patients according to the 1997 AJCC stage classification system. 9 After restaging, 63 patients were identified as having 1997 AJCC stage I and II NPC. Of these 63 early-stage NPC patients, 3 patients were excluded for the following reasons: incomplete RT in 1 patient, CCRT in 1 patient, and neoadjuvant CT followed by CCRT in 1 patient. Among the remaining 60 patients with stage I to II disease, 31 patients were treated with RT alone, and 29 patients were treated with neoadjuvant CT followed by RT (CT/RT).
Pretreatment evaluations included taking a patient history, physical examination, endoscopic examination of the nasopharynx, oropharynx, and larynx, and computed tomography scan or MRI of the head and neck. Of all of the evaluated patients, 41 patients were evaluated by computed tomography only, 2 patients by MRI only, and 17 patients by computed tomography and MRI. Chest radiographs, a radionuclide bone scan, complete blood counts, and serum chemistry measurements were noted for the patients. An antibody titer against various Epstein-Barr viral (EBV) proteins such as early antigen, viral capsid antigen, and nuclear antigen were checked for only four patients; the presence of EBV DNA was not determined for any of the patients.
For patients treated with RT alone (RT alone group), 22 (71%) patients had stage IIB disease. The median age of patients in this group was 47 (range, 17-61) years, with 21 males (68%) and 10 females (32%). Squamous cell carcinoma was identified by histology in 2 (7%) patients, a nonkeratinizing carcinoma was identified in 6 (19%) patients, and an undifferentiated carcinoma was identified in 23 (74%) patients. The median interval from biopsy to beginning of irradiation was 20 (range, 10 -155) days. The mean nodal size was 2.0 cm, and the median nodal size was 2.0 (range, 1-3) cm.
For patients treated with neoadjuvant CT followed by RT (CT/RT group), 21 (72%) patients had stage IIB disease. The median age was 55 (range, 10 -71) years, with 23 (79%) males and 6 (21%) females. Squamous cell carcinoma was identified by histology in 4 (14%) patients, a nonkeratinizing carcinoma was identified in 4 (14%) patients, and an undifferentiated carcinoma was identified in 21 (72%) patients. The median interval from biopsy to beginning of irradiation was 89 (range, 48 -174) days. The RT ϭ radiotherapy; CT ϭ chemotherapy.
mean nodal size was 2.6 cm, and the median nodal size was 2.0 (range, 1-6) cm. The patient characteristics of all 60 patients are shown in Table I . Cross-tabulations revealed a good balance between the two treatment groups concerning age, sex, histology, T stage, N stage, node size, and radiation dose. However, the treatment era (1986 -1995 vs. 1996 -2004 ) and the delays between initial biopsy and RT start (Յ81 d vs. Ͼ81 d) were significantly different between the two groups. There was no fixed indication of neoadjuvant CT. However, there was a tendency seen that induction CT was preferred in the recent 10 years. Figure 1 shows the distribution of patients according to the year of treatment.
We have performed subgroup analysis for stage IIB disease because, at that stage, patients are expected to show an advantage with CT. Table II shows the patient characteristics of those with stage IIB disease.
Radiotherapy
The technique and dosing of RT between the two groups were the same. Nasopharynx and upper neck lymphatics were treated with 4 or 6 MV photons through bilateral opposed fields and reserved 10 or 15 MV photons for an off-cord boost and 9 or 12 MeV electrons for palpable nodes boost. The lower neck and supraclavicular fossa were treated through an anterior single field with midline shielding. No patient received three-dimensional conformal RT or intensity-modulated RT. RT was administrated five times a week in 1.8 to 2 Gy fractions per day. The spinal cord was limited to a total dose of 45 Gy. The accumulated dose was 66.6 to 72 (median dose, 70.2) Gy to the primary site, 54 to 72 (median dose, 63) Gy to the involved nodal areas, and 30.6 to 60 (median dose, 45) Gy to the uninvolved nodal areas, respectively. The response of RT was assessed 1 to 4 months after the completion of RT.
Neoadjuvant Chemotherapy
Treatment with cisplatin (100 mg/m 2 slow bolus injection on d 1), and 5-fluorouracil (1,000 mg/m 2 over 12 hr infusion on d 1-5) was given to 26 patients. The other three patients received various regimens. Details of the CT regimens are shown in Table III . Twenty-six (90%) patients received three cycles of planned CT delivered 3 weeks apart. Three patients received two cycles of CT because of toxicity (2 patients) and poor response to CT (1 patient). The response to neoadjuvant CT was assessed 2 to 4 weeks after completion of the last cycle of CT; the response was determined clinically by nasopharyngoscopy and radiologically by computed 
Follow-Up
All patients were monitored by nasopharyngoscopy and by physical examination at 3-month intervals for the first 2 years and at 4 to 6 month intervals thereafter. All patients had computed tomography or MRI performed every 6 months for the first 2 years and annually for the following 3 years.
Statistical Methods
The 2 test or Fisher's exact test for categorical variables and the Student t test for continuous variables was used to evaluate differences between groups. The duration of DFS and OS were calculated from the start of treatment until tumor recurrence or until a patient death was observed. The median follow-up time was 124.5 (range, 5-239) months. Survival curves were calculated according to the Kaplan-Meier method. 18 The log-rank test was used to assess the statistical significance of specific patient subsets. Multivariate analysis using the Cox proportional hazard model 19 was also performed to test the prognostic significance of the variables.
RESULTS

Initial Tumor Response
The tumor response to neoadjuvant CT was a complete response (CR) in 5 (18%) patients, partial response in 23 (79%) patients, and stable disease in 1 (3%) patient. After completion of RT, all of the patients had CR. For patients who were treated with RT alone, all achieved CR.
Patterns of Failure
The 5-year locoregional failure-free (LRFF) rates for the RT group and the neoadjuvant CT followed by RT group (CT/RT) were 84% and 77%, respectively (P ϭ .728). For stage IIB disease, the corresponding 5-year LRFF rates were 82% and 67%, respectively (P ϭ .368). Figures  2 and 3 show LRFF rates for all patients and patients with stage IIB disease, respectively.
For the RT group, 3 of 31 patients developed distant metastases. For the CT/RT group, 4 of 29 patients developed distant metastases. The 5-year distant metastasisfree (DMF) rate was 93% for the RT group as compared with 86% for the CT/RT group (P ϭ .433). For stage IIB disease, the corresponding 5-year DMF rates were 91% Fig. 3 . Locoregional failure-free rates for stage IIB patients according to the treatment modality. and 81%, respectively (P ϭ .324). Except for one T1N0 patient, all of the patients with distant metastases were N1 patients.
Survival
The 5-year DFS rates for the RT group and CT/RT group were 81% and 71%, respectively. The corresponding 10-year DFS rates were 77% and 71%, respectively. There was no significant difference for these values between the two groups (P ϭ .562) (Fig. 4) . For stage IIB disease, the 5-year DFS rate of the RT group and CT/RT group were 77% and 60%, respectively (P ϭ .284) (Fig. 5) .
The 5-year OS rates for the RT group and the CT/RT group were 84% and 79%, respectively. The corresponding 10-year OS rates were 77% and 68%, respectively. There was no significant difference for these values between the two groups (P ϭ .625) (Fig. 6) . For stage IIB disease, the 5-year OS rate of the RT group and CT/RT group were 82% and 76%, respectively (P ϭ .502) (Fig. 7) .
Analysis of Prognostic Factor
To adjust for prognostic factors, the following parameters were included in the analysis: age (Ͻ50 vs. Ն50 yr), sex, histology (undifferentiated vs. others), T stage (1 vs. 2), N stage, waiting time (Յ81 vs. Ͼ81 d), year of treatment (until 1995 vs. since 1996), and the use of CT. In univariate analysis for all patients, N stage was the only statistically significant factor for DFS (P ϭ .048) (Table  IV) . Within stage IIB disease, waiting time (Ͼ81 d) was the only significant factor for locoregional failure (P ϭ .049) ( Table V) .
In multivariate analysis for all patients, N stage reached marginal significance for DFS (P ϭ .050). Multivariate analysis for stage IIB disease showed that waiting time (Ͼ81 d) had a significant effect on the incidence of locoregional failure (P ϭ .044).
DISCUSSION
The aim of the present study was to compare the outcomes of RT alone with neoadjuvant CT followed by RT for early-stage NPC. There were no significant differences in the LRFF, DMF, DFS, and OS rates between the two groups. N stage was significantly correlated with the DFS rate. Therefore, we performed subgroup analysis in a more homogeneous group of patients with stage IIB disease. Although it was not significant, more obvious differences concerning LRF, DMF, and DFS between the two groups were observed in stage IIB disease. In general, adding CT to RT is expected to show better outcomes. Also, in our hospital data for advanced NPC, 16 we have observed neoadjuvant CT is better than RT alone. We were therefore embarrassed with the results of the present study. We have found that there were significant differences between the two groups regarding treatment era and the waiting time from biopsy to RT start. Multivariate analysis revealed that delaying RT for more than 81 days was significantly associated with an increased risk of locoregional failure in the subgroup of patients with stage IIB disease (P ϭ .044). Patients with a waiting time of more than 81 days showed poor outcomes. Figures 8 to 11 show LRFF, DMF, DFS, and OS rates between the two groups (Յ81 d vs. Ͼ81 d).
In the present study, the median time from the first day of CT to the first day of RT was 77 (range, 3 -160) days. Although there were no statements concerning the median time from CT to RT in other neoadjuvant studies, 13, 14, 20, 21 we can estimate the time by using the percentage of patients who completed three cycles of CT and the percentage of patients who had treatment interruption. The schedule of CT was two or three cycles every 21 days in most neoadjuvant CT studies. In the Asian Oceania Clinical Oncology Association 13 and Guangzhou trials, 14 only 72% and 32% of patients completed three cycles of CT, respectively. In the present study, most patients (90%) completed three cycles of CT, and only three (10%) patients had started RT within 63 days from the first day of CT. It is thought that the neoadjuvant patient group of the present study had more patients with longer delays than in other studies.
Few studies 22 to 24 have evaluated the risk of delaying radical RT for head and neck carcinomas. Fortin et al. 22 observed that a delay of more than 40 days was significantly associated with an increased risk of local and neck failure and poorer survival relative to patients treated in less than 30 days or between 31 and 40 days in early-stage head and neck carcinoma receiving radical RT. Delay was defined as the time from initial evaluation by a radiation oncologist to the beginning of RT in that study. However, Lee and Chan 23 observed that a waiting time of more than 28 days had no significant impact on local, regional, and distant failure in T1 NPC patients. They found that the rate of neck failure increased with the delay time in node negative patients without elective neck irradiation. However, most radiation oncologists treat N0 patients with elective neck irradiation. Also, Lee and Chan did not use conventional fractionation. RT was given at 50.4 Gy in 12 fractions over 38 days in that study. It is thought that a delay of more than 28 days is too short to reveal any differences. In the Fortin et al. 22 study, the total median delay from biopsy to RT was 28 days in 1989, 46 days in 1995, and 55 days in 1997. Barton et al. 24 observed that longer waiting time was not significantly associated with worse local control in early larynx cancer. However, they said that larger and more aggressive tumors might have received priority for the RT start. Also, the median time from biopsy to RT start was too short, 24 days in that study.
This study was a retrospective study and is not intended to determine the effect of delay on the outcome of patients receiving radical RT for NPC, and, therefore, treatment modality, RT alone or CT/RT, was quite different between the two groups. However, for ethical reasons, a prospective, randomized study is unlikely to be carried out. Multivariate analysis showed that, even when correcting for age, treatment modality (RT vs. CT/RT), a longer delay of more than 81 days remained a significant factor of locoregional failure in stage IIB disease. We believed that delay of RT might be a cause of poor outcome in the CT/RT group.
Another possible hypothesis is that the CT/RT group had a larger subset of patients with a poor prognosis by chance, although possible prognostic factors such as age, sex, histology, T stage, N stage, nodal size, and overall stage were distributed evenly between patients in the RT and CT/RT groups. It has been suggested that a determination of levels of EBV DNA could be of value in pretreatment risk stratification and cancer staging. Recently, Leung et al. 25 reported the long-term follow-up results for EBV DNA as a prognostic biomarker for NPC. These investigators studied 155 stage I and II patients and 221 stage III and IV patients. For stage I and II disease, high EBV DNA levels strongly predicted inferior survival (P ϭ .0003), in contrast to the lack of significant discrimination by 1997 AJCC stage alone (P ϭ .27). The 5-year survival rates for the low-and high-level EBV DNA groups for stage II disease were 90% and 63%, respectively. The 5-year survival rate for the low-level EBV DNA group for stage III and IV disease was 64%. In our study, copy levels of EBV DNA were not determined in patients.
In summary, based on this limited retrospective study, the addition of neoadjuvant CT to RT did not improve LRFF, DMF, DFS, and OS rates in early-stage NPC. Also, the poor outcomes of induction CT were more obvious in stage IIB disease, which was expected to show more benefits. We also found that delay of RT through performance of neoadjuvant CT was associated with increased locoregional failure in stage IIB disease. The results of the present study suggest that curative modality RT should not be compromised by neoadjuvant CT in early-stage NPC.
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